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Septin makes a fence around cilia
Hu et al., Science 2010; 329: 436–439; doi:10.1126/science.1191054
Cilia (or flagella) are specialized domains of the cell membrane 
composed of proteins, many of which are restricted to the cil-
iary membrane and excluded from the surrounding plasma 
membrane. These organelles are present in most cells and are 
located on the apical membrane in epithelia. A large number of 
renal cystic diseases due to mutations in ciliary proteins—now 
termed ciliopathies—have been identified. Recently, Hu et al. 
addressed the basic question of how the proteins are targeted 
to the cilia and how they remain there. These studies used 
fluorescence recovery after photobleaching, in which fluores-
cently labeled proteins are first bleached with a high-intensity 
light and then the diffusion of fluorescently labeled proteins 
into that bleached target area is examined. Using ciliated inner 
medullary collecting duct cells, the authors showed that when 
the whole flagellum was bleached, no new fluorescent mem-
brane proteins were able to enter the flagellum. However, an 
intraflagellar protein, IFT88, was freely mobile. But when a 
small spot on the cilium was bleached, the membrane pro-
teins could readily diffuse from other parts of the cilium to 
the bleached spot, suggesting that the proteins were mobile 
in the plane of the membrane. This finding suggests that these 
ciliary membrane proteins are ‘trapped’ by some mechanism 
that prevents them from diffusing from the cilium into the api-
cal plasma membrane. It is known that the yeast bud and the 
vertebrate sperm ‘tail’ also contain proteins that do not diffuse 
into the adjacent membrane; they are prevented by a barrier of 
proteins called septins, which have an enzymatic function as 
guanosine triphosphatases. The mammalian genome contains 
a large number of septin genes. Hu et al. discovered that septin 
2 (SEPT2) was localized in a ring structure at the base of the 
cilia and that knockdown of this protein allowed the proteins 
to readily diffuse into the apical plasma membrane. In cells 
with severe depletion of the septin molecule, there were no 
cilia, which clearly shows the critical role of these proteins in 
the formation of this unique organelle.
It would be interesting to find out whether mutations of SEPT2 
might cause a polycystic disease phenotype.
Qais Al-Awqati
Mitochondrial superoxide as a 
target to lower blood pressure
Dikalova et al., Circ Res 2010; 107: 106–116; doi:10.1161/
CIRCRESAHA.109.214601
Under normal homeostasis, a small percentage of electrons 
from the electron transport chain in mitochondria reduce oxy-
gen to form superoxide (O2
–). However, this leak of electrons 
increases in a variety of conditions, such as advanced age, 
atherosclerosis, and ischemia/reperfusion injury. Mitochon-
dria contain a unique form of superoxide dismutase (SOD), 
the manganese-containing mitochondrial SOD (SOD2), 
which is critical in protecting against excessive production 
of O2
–. Indeed, mice lacking this enzyme die of a cardiomy-
opathy within 10 days of birth, and mice lacking one allele of 
SOD2 (SOD2+/– mice) develop hypertension with aging and 
in response to a high-salt diet. Several forms of hypertension 
have been associated with increased reactive oxygen species 
(ROS) production in the vasculature, kidney, and locations of 
the central nervous system that control blood pressure. Angi-
otensin II (Ang II) increases ROS production in these sites, 
and there is great interest in elucidating the sources of ROS 
in hypertension. Ang II stimulates NADPH oxidase, and mice 
lacking components of this enzyme are somewhat resistant 
to both Ang II-dependent and salt-dependent hypertension. 
Needless to say, another potential source of ROS is mito-
chondria, and previous studies found that Ang II increased 
mitochondrial ROS. Dikalova et al. examined SOD2 in 
endothelial cells and in hypertension. They found that Ang II 
increased endothelial mitochondrial O2
– production and that 
the mitochondria-targeted antioxidant dismutase mimetic 
(mitoTEMPO) decreased mitochondrial and cellular O2
– and 
restored the level of bioavailable nitric oxide. Similar results 
were obtained by overexpressing SOD2. Importantly, in vivo 
treatment with mitoTEMPO lowered blood pressure in mice 
made hypertensive with Ang II or DOCA-salt, whereas non-
targeted TEMPOL was not effective. Transgenic mice over-
expressing SOD2 demonstrated attenuated Ang II-induced 
hypertension (Figure) and vascular oxidative stress similar 
to those seen in mice treated with mitoTEMPO.
Thus, the study shows that mitochondrial O2
– is important 
for the development of hypertension and that antioxidant strat-
egies specifically targeting this organelle could be a therapeutic 
approach for its control.
Juan Oliver
Systolic blood pressure in SOD2-overexpressing transgenic (TgSOD2) 
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Activation of hepatic erythropoietin 
synthesis as treatment for anemia  
of renal failure
Kapitsinou et al., Blood advance online publication, 13 July 2010, 
doi:10.1182/blood-2010-02-270322
Minamishima and Kaelin, Science 2010; 329: 407; doi:10.1126/science.1192811
During embryogenesis, erythropoietin (EPO) is produced by 
hepatocytes, but late in gestation, EPO production switches to the 
kidney, where fibroblast-like peritubular interstitial cells are EPO’s 
main source in the adult. Although the liver retains the ability to 
produce EPO in response to hypoxic stimuli, impairment of renal 
EPO synthesis causes anemia that needs treatment with recom-
binant EPO. Hypoxia-inducible factors-1 (HIF-1) and -2 (HIF-2) 
mediate the cellular adaptation to hypoxia by stimulating erythro-
poiesis, angiogenesis, and anaerobic glucose metabolism. Under 
normoxia, the α-subunit of HIFs is prolyl hydroxylated by prolyl 
hydroxylase domain (PHD) proteins, leading to its polyubiquitina-
tion by the von Hippel–Lindau protein and subsequent degrada-
tion. Under hypoxic conditions, however, PHD activity decreases 
and HIFα accumulates; binding of HIFα to HIFβ transcription-
ally activates genes such as EPO. The possibility of reactivating 
hepatic EPO synthesis as a therapy for the anemia of renal failure 
has been approached in two recent communications. Kapitsinou 
et al. made use of Cre-loxP technology to determine which HIF is 
responsible for most renal and hepatic EPO synthesis. They found 
that mice with specific kidney ablation of HIF-2α had severe ane-
mia, demonstrating that HIF-2 is the critical factor for normal 
renal EPO production. Further, as these mice had normal global 
kidney function, they generated an elegant experimental model 
of ‘renal anemia’ without uremia. The authors also found that, in 
their mice, hepatic activation of EPO could be modestly increased 
by hypoxia and that, like in the kidney, hepatocyte HIF-2α was 
also responsible for its synthesis. Moreover, treatment of the mice 
with a compound that inhibits PHD and thus stabilizes both HIF-1 
and HIF-2 increased their hematocrit (Figure), showing that hepa-
tocyte EPO synthesis can be enhanced. Using another approach, 
Minamishima and Kaelin examined the exact roles of PHDs in 
hepatic EPO synthesis. The primary HIFα prolyl hydroxylase is 
PHD2, and its silencing in adults increases renal, but not hepatic, 
EPO production and causes polycythemia. Two other enzyme vari-
ants, PHD1 and PHD3, are believed to fine-tune the HIF response. 
To determine whether PHD inactivation could reactivate hepatic 
EPO production, these authors generated mice with livers lack-
ing PHD1, PHD2, PHD3, or combinations thereof. They found 
that hepatic inactivation of PHD1, PHD2, or PHD3 alone did not 
increase EPO or hematocrit values. However, loss of all three PHDs 
dramatically increased EPO and hematocrit values. These studies 
indicate that hepatic EPO production may be a useful method to 
treat renal anemia and that compounds that inactivate all three 
PHDs are likely to be needed.
Juan Oliver
A randomized, controlled trial of 
early versus late initiation of dialysis
Cooper et al., N Engl J Med 2010; 363: 609–619
The proper timing for initiation of dialysis has been debated. While 
studies of dialysis patients suggesting that greater levels of clearance 
are associated with longer survival indirectly support the earlier 
initiation of dialysis, observational studies with the inherent selec-
tion bias imposed by the clinical decision to begin dialysis early 
demonstrate worse survival in this group. A randomized trial of 828 
patients recruited in Australia and New Zealand at 32 centers exam-
ined the effect of initiation of dialysis at an estimated glomerular 
filtration rate (GFR) between 10 and 14 ml/min (early-start group) 
or later initiation of dialysis at an estimated GFR of 5–7 ml/min 
(late-start group). The primary outcome was all-cause death. The 
secondary outcomes included individual cardiovascular or infec-
tious events and complications of dialysis related to either vascular 
access or the procedure. The median time from randomization 
to initiation of dialysis was 1.8 months in the early-start group as 
compared with 7.4 months in the late-start group. At the time of 
initiation of dialysis, the estimated GFR was 12.0 ml/min in the 
early-start group and 9.8 ml/min in the late-start group. While a 
greater separation was prescribed by the protocol, these differences 
were statistically significant. There was no significant difference in 
survival between patients in the late-start group and patients in the 
early-start group (hazard ratio for death in the early-start group was 
1.04, 95% confidence interval 0.83–1.30). None of the secondary 
outcomes, including cardiovascular events, infectious events, and 
treatment-associated complications, were significantly different 
between groups. Additionally, there were no significant differences 
in quality of life between the two groups. Finally, the lack of an effect 
of early start on all-cause death appeared to be consistent among all 
subgroups identified by age, sex, presence of diabetes, body mass 
index, cardiovascular disease, and nutritional stores.
The decision to initiate dialysis in any specific patient is based 
on patient symptoms, laboratory parameters, and some compo-
nents of patient autonomy or assessment of quality of life. On the 
basis of the observational data, the potential for better outcomes 
related to better clearance versus increased risk related to earlier 
use of vascular access procedures could not be determined. This 
randomized trial suggests that, on a population level, no benefit 
of the earlier initiation of dialysis exists.
Lynda Szczech
Prolyl-4-hydroxylase inhibition (PHI) with GSK1002083 raised 
hematocrits (Hct; left) and serum Epo levels (right) in mice with deletion 
of renal HIF-2α.
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